Anaptysbio (ANAB) Research & Development (2016 - 2026)

Anaptysbio (ANAB) has 11 years of Research & Development data on file, last reported at $34.0 million in Q1 2026.

• Quarterly Research & Development fell 17.46% year-over-year to $34.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $128.8 million (down 23.33% YoY) and the FY2025 annual result came in at $136.0 million, down 17.01% from the prior year.
• Research & Development climbed to $34.0 million in Q1 2026, from $25.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $42.6 million in Q4 2024 to a low of $20.8 million in Q2 2022.
• A 5-year average of $32.6 million and a median of $33.5 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2023 — Research & Development surged 57.95% — and 2025, when it slumped 39.99%.
• Tracing ANAB's Research & Development over 5 years: stood at $23.4 million in 2022, then surged by 43.43% to $33.5 million in 2023, then rose by 27.04% to $42.6 million in 2024, then slumped by 39.99% to $25.6 million in 2025, then soared by 32.99% to $34.0 million in 2026.
• The last three Research & Development figures came in at $34.0 million (Q1 2026), $25.6 million (Q4 2025), and $31.4 million (Q3 2025), per Business Quant data.